Nosis Bio Enters into Strategic Collaboration with Johnson & Johnson for the Design and Development of Cell-Targeted Delivery Vehicles

Nosis Biosciences, an AI-enabled biotechnology company focused on the design and development of RNA medicines for challenging cell types, announced today that it has entered into a strategic collaboration with Johnson & Johnson.* This collaboration combines the drug discovery and clinical development expertise from Johnson & Johnson with Nosis’ Connexa™ platform, an AI-powered drug design and delivery platform, to enable extra-hepatic therapeutic access to multiple and challenging cell types implicated in chronic disease.

Nosis has developed a breakthrough solution for the efficient design & development of cell-targeted RNA precision medicines. Nosis’ platform, Connexa™, combines a proprietary atlas of cell-specific internalizing receptor targets, physics-aware machine learning, generative AI drug design, and high throughput in vivo data characterization to rapidly advance cell-targeted medicines into therapeutic development.

“Nosis’ Connexa is the first universal platform for the design and development of cell-targeted precision medicines for extrahepatic cell types. We have demonstrated the power of this approach across multiple tissue types to significantly accelerate the safe and effective development ofRNA medicines beyond the liver,” said Jim Martineau, Co-founder and CEO of Nosis Bio. "We look forward to collaborating with Johnson & Johnson tounlock therapeutic access to important cell types where we see enormous opportunity to bring new precision medicines to patients.”

 *Legal entity, Janssen Biotech, Inc.

About Nosis Biosciences

Nosis Biosciences designs and develops cell-targeted RNA therapeutics, unleashing the full potential of precision medicines in the treatment of chronic disease. Nosis’ platform, Connexa™, combines a proprietary atlas of cell-specific internalizing receptor targets, physics-aware machine learning, generative AI drug design, and high throughput in vivo data characterization to rapidly advance cell-targeted medicines into therapeutic development.

Nosis Biosciences is based in Berkeley, CA with a team ofexperts in deep learning, molecular design, in vivo pharmacology, and RNAtherapeutic development. Nosis is advancing an internal pipeline of RNA therapeutics focused in chronic disease across multiple key cell types while also collaborating in other areas with global biopharma.